CRISPR and HCA Healthcare Outperform S&P 500 with 44% and 58% Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- CRISPR's Strong Performance: CRISPR Therapeutics' stock has risen 44% this year, driven by promising early-stage clinical studies, particularly with CTX310 aimed at lowering LDL cholesterol, which could lay the groundwork for future profitability despite no current approvals.
- HCA Healthcare's Robust Growth: HCA Healthcare's shares surged 58%, fueled by strong financial results and recognition of 33 hospitals among Fortune's top 100, although future performance may be impacted by policy uncertainties, the company continues to grow its market share, showcasing a strong competitive edge.
- Market Outlook Analysis: CRISPR anticipates launching new products in 2026, which could significantly enhance its market position, while HCA must monitor U.S. federal policy changes that could affect patient demand and, consequently, its future results.
- Investment Recommendations: Despite the high risks associated with CRISPR, its potential product breakthroughs and HCA's solid performance make both stocks attractive for investment in 2026, particularly for long-term investors.
CRSP
$56.71+Infinity%1D
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 56.460
Low
40.00
Averages
73.41
High
105.00
Current: 56.460
Low
40.00
Averages
73.41
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
